


Discover & Deliver: Biopharmaceutical Innovators Pledge Safety & Effectiveness as Top Priority for Coronavirus Vaccine

As children, teachers, and school administrators head back to school, a potential COVID-19 vaccine is top of mind for many.

There are currently over [700 clinical trials](#) taking place for COVID-19-related vaccines and treatments across all 50 states. In communities large and small across the country, innovative companies, hospitals, and universities have banded together to identify scientific advancements to combat COVID-19.

The business community believes one thing is clear: we must continue to follow the science.



What's new: Today, nine of the leading biopharmaceutical companies [signed a pledge](#) to uphold the integrity of the scientific process. Three of the signatory companies – AstraZeneca, Moderna, and Pfizer – are hosting late-stage clinical trials for promising COVID-19 vaccines, with the hope of identifying an effective candidate by early this fall.

While time is of the essence, the companies recognize that the safety and efficacy of the vaccine must continue to be their top priority.

What's in the pledge: The companies commit to “developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles” to ensure that science – not speed – guides us to an effective vaccine candidate.

With the leading biopharmaceutical companies on the task, the Chamber trusts that we will soon have a vaccine to protect our students, teachers, and communities against COVID-19.

– Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center